Table 4—

Distribution of adverse outcomes after 3 years among the groups of the consensus classification

Group 0 (no neuropathy)OR (groups 1–3b)Group 1 (neuropathy)OR (groups 1–3b)Group 2 (neuropathy, PVD and/or deformity)OR (groups 2–3b)Group 3a (previous ulcer, no amputation)OR (groups 3a–3b)Group 3b (previous amputation)TotalP
n7921514319213
Follow-up ulcer4 (5.1)100.0 (20.4–491.0)3 (14.3)32.0 (5.6–181.6)7 (13.7)33.5 (7.7–145.6)24 (55.8)4.2 (1.1–16.7)16 (84.2)54 (25.4)<0.001
Follow-up amputation07.6 (4.5–12.8)01.6 (1.1–2.2)1 (2.0)29.2 (3.3–260.1)9 (20.9)NS7 (36.8)17 (18.1)<0.001
Toe/ray001 (2.0)6 (14.0)1 (5.3)8 (3.8)
Midfoot/TMA0002 (4.7)3 (15.8)5 (2.3)<0.001
BKA or AKA0001 (2.3)3 (15.8)4 (1.9)
Reamputations0004.2 (2.7–6.4)4 (9.3)NS3 (15.8)7 (41.1)<0.001
Follow-up bypass06.0 (3.8–9.3)02.3 (1.6–3.3)1 (2.0)NS2 (4.7)NS3 (15.8)6 (2.8)0.001
  • Data are n (%) or OR (95% CI) unless otherwise indicated. For follow-up ulcer, follow-up amputation, toe/ray, midfoot/transmetatarsal amputation (TMA), below-the-knee amputation (BKA), or above-the-knee amputation (AKA), and reamputations, P < 0.001; for follow-up bypass, P = 0.001.